Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13256449 | 0.87 | PDE10A (0.34) | PDE10AHDAC9CYP17A1CYP1A2 | |
| SCHEMBL18034963 | 0.81 | PDE10A (0.42) | PDE10AHDAC9CYP17A1CYP1A2 | |
| SCHEMBL12718669 | 0.74 | HRH3 (0.36) | PDE10AHRH3 | |
| SCHEMBL13283524 | 0.73 | PDE10A (0.35) | PDE10AHDAC9CYP17A1CYP1A2 | |
| SCHEMBL12691764 | 0.72 | HDAC9 (0.38) | PDE10AHDAC9 | |
| SCHEMBL19498087 | 0.71 | PDE10A (0.34) | PDE10AHDAC9CYP17A1CYP1A2 | |
| SCHEMBL16624092 | 0.69 | HDAC9 (0.38) | HDAC9HRH3OGA | |
| SCHEMBL16210618 | 0.68 | PNMT (0.34) | PDE10AHDAC9 | |
| SCHEMBL19558163 | 0.67 | HRH3 (0.44) | HRH3OGA | |
| SCHEMBL12718664 | 0.65 | HRH3 (0.36) | HRH3OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| WO-2015050212-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日産化学工業株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | PDE10A 1643/4885HDAC9 2178/4885HRH3 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.